NGNan Gao

Nan Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nan Gao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng Ji

    Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    2 shared publications
  • Jiaojiao Liu

    Department of Pharmacy Nanjing Drum Tower Hospital, Dalian Medical University Nanjing China

    1 shared publication
  • Li Li

    Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

    1 shared publication
  • Ruiwen Hu

    Department of Pharmacy, Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, China, cpu.edu.cn

    1 shared publication
  • Tianwei Gu

    Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China

    1 shared publication
  • Ting He

    Department of Pharmacy, Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, China, cpu.edu.cn

    1 shared publication

Latest Publications

  • Open Access

    Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response

    by Ruiwen Hu, Xiaodie He, Nan Gao, Ting He, Li Li, Tianwei Gu, Xin Gu, Cheng Ji

    Objective: To investigate the association between serum human epidermal growth factor receptor 2 (HER2) levels and metabolic syndrome (MS) in women and to explore the relationship between HER2 and the use of commonly prescribed metabolic medications. Methods: A total of 532 women who visited Nanjing Drum Tower Hospital between January 2021 and January 2023 were enrolled. Participants were classified into a non‐MS group ( n = 278) and an MS group ( n = 254) according to the diagnostic criteria of the Chinese Diabetes Society (2020 edition). General characteristics and serum HER2 levels were compared between groups. Based on serum HER2 levels, participants were further categorized into quartiles (Q1 [< 7.4 ng/mL], Q2 [7.4–8.5 ng/mL], Q3 [8.6–9.9 ng/mL], and Q4 [> 9.9 ng/mL]), and clinical parameters were compared among these groups. Spearman correlation analysis was performed to examine the relationships between HER2, MS‐related indicators, and medication use. Logistic regression analysis was conducted to identify independent risk factors for MS. Results: Serum HER2 levels were significantly higher in the MS group compared with the non‐MS group (8.10 [7.10–9.10] vs. 9.25 [8.10–10.80] ng/mL, p < 0.001). The prevalence of MS increased progressively across HER2 quartiles: 31.30% (Q1), 36.43% (Q2), 50.00% (Q3), and 72.39% (Q4) ( p < 0.001). Serum HER2 levels were positively correlated with body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), fasting serum insulin (FINS), fasting C‐peptide (FCP), total cholesterol (TC), triglycerides (TG), and low‐density lipoprotein cholesterol (LDL‐C) (all p < 0.001) and negatively correlated with age, high‐density lipoprotein cholesterol (HDL‐C), and the use of renin–angiotensin system inhibitors and statins (all p < 0.001). Logistic regression analysis showed that higher HER2 levels remained a significant risk factor for MS after adjustment for confounders, and compared with Q1, the risk of MS in Q4 remained significantly higher in fully adjusted models. Conclusion: The use of renin–angiotensin system‐targeting antihypertensive agents or statins was associated with significantly reduced serum HER2 levels. Increasing serum HER2 levels correlated with a higher prevalence of MS, suggesting that elevated HER2 may serve as an independent risk factor and a potential biomarker for MS in women.

  • Open Access

    An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

    by Zhuolin Zhou, Nan Gao, Jiaojiao Liu, Xuerong Ma, Zhijuan Ge, Cheng Ji

    Aim: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population. This study aims to develop a predictive model that accurately identifies the risk of MASLD among T2DM patients. Materials and methods: Clinical data were collected from T2DM patients hospitalised at Nanjing Drum Tower Hospital between January 2018 and May 2025. Eight machine learning methods were developed to predict the risk of MASLD in T2DM patients. The discriminatory ability of the models was evaluated using area under the receiver operating characteristic curve (AUROC), area under the precision‐recall curve (AUPRC), accuracy, recall, negative predictive value, positive predictive value, and F1 score. Calibration curves and decision analysis curves were employed to evaluate the calibration and clinical utility. The models were interpreted using the Shapley additive explanations method, and unsupervised clustering was performed to identify potential high‐risk subgroups. Results: A total of 3836 T2DM patients constituted the complete dataset, with a MASLD incidence rate of 55.9%. Thirteen feature variables were selected for model construction, and the XGB model achieved optimal overall performance, with an AUROC of 0.873 and an AUPRC of 0.904. Unsupervised clustering identified several high‐risk subgroups with distinct metabolic characteristics. Conclusion: The model developed enables reliable and interpretable MASLD risk prediction in T2DM patients based on selected commonly available clinical data, providing a practical tool for routine identification and stratified management.